LANCASTER, Calif.--(BUSINESS WIRE)--
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for pharmaceutical discovery and development, today announced that chairman and chief executive officer, Walt Woltosz, will present at the 10th annual LD Micro Main Event at 4 p.m. PT on Wednesday, December 6, 2017.
The 10th annual LD Micro Main Event will highlight many of the most influential companies in the microcap space including top performers from the past decade, as well as the next generation of names looking to make their mark. The conference will be held December 5-7, 2017 at the Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, CA.
Management will be available during the day on December 6 for one-on-one meetings. For more information about the conference, or to schedule a one-on-one meeting with management, please contact Hayden IR at [email protected].
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. We are investors, first and foremost. What started out as a newsletter highlighting unique companies has transformed into several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LD Micro launched ldmicro.com as a portal to provide exclusive intraday information on the entire sector, including the first pure microcap index (LDMi) which covers stocks in North America with market capitalizations between $50 million and $300 million.
About Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury and nonalcoholic fatty liver disease. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.
Follow us on Twitter | LinkedIn
View source version on businesswire.com: http://www.businesswire.com/news/home/20171116005505/en/
